Lilly buys cancer biotech ARMO for $1.6bn
Lilly adds pancreatic cancer drug to pipeline
X
Lilly buys cancer biotech ARMO for $1.6bn
https://pharmaphorum.com/news/lilly-buys-cancer-biotech-armo-for-1-6bn/
pancreatic cancer
AI-backed blood test could reduce reliance on cancer drugs
Approach could reduce use of cancer drugs.
Smartphone selfie app can diagnose pancreatic cancer
App could help identify early signs of the disease.
NICE recommends Celgene pancreatic cancer drug
Abraxane finally gets NHS funding following price cut.
NICE rejects Shire pancreatic cancer drug
Onivyde not eligible for Cancer Drugs Fund, says NICE.
Shire’s Onivyde pancreatic cancer drug approved in EU
Drug approved in metastatic adenocarcinoma of the pancreas.
Shire’s Onivyde recommended by EU regulators
New option likely in advanced pancreatic cancer.
